Bayer is the most recent winner of the reputation stakes according to a survey conducted by The Reputation Institute.  The German company has maintained its position at the top for the fourth year in a row.

Roche, Abbot, Lilly and GSK in that order followed Bayer.

Data was collated across 15 countries and 61,000 general public members over February and March of this year.  Companies were ranked on reputation, products & services, innovation, workplace governance, citizenship, leadership and financial performance.

Of the companies in the study, Novo Nordisk and Novartis were those shown to have declined in reputation.

Interestingly enough and found in the conclusion of the study, the reputation of global pharma is mixed with 34% perceiving the industry as having an excellent reputation.  Also, it seems those in Russia, Australia and the US remain positive and have scored the industry as strong/robust compared to other countries who scored the industry lower.